Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Selective sodium glucose cotransporter-2 inhibitor (SGLT2i) treatment promotes urinary glucose excretion, thereby reducing blood glucose as well as body weight. However, only limited body weight reductions are achieved with SGLT2i treatment. Hyperphagia is reportedly one of the causes of this limited weight loss. However, the effects of SGLT2i treatment on systemic energy expenditure have not been fully elucidated. Herein, we investigated the acute effects of dapagliflozin, a SGLT2i, on systemic energy expenditure in mice. Eighteen hours after dapagliflozin treatment oxygen consumption and brown adipose tissue (BAT) expression of ucp1, a thermogenesis-related gene, were significantly decreased as compared to those after vehicle treatment. In addition, dapagliflozin significantly suppressed norepinephrine (NE) turnover in BAT and c-fos expression in the rostral raphe pallidus nucleus (rRPa) which contains the sympathetic premotor neurons responsible for thermogenesis. These findings indicate that the dapagliflozin-mediated acute decrease in energy expenditure involves a reduction in BAT thermogenesis via decreased sympathetic nerve activity from the rRPa. Furthermore, common hepatic branch vagotomy abolished the reductions in ucp1 expression and NE contents in BAT and c-fos expression in the rRPa. In addition, alterations in hepatic carbohydrate metabolism, such as decreases in glycogen contents and upregulation of phosphoenolpyruvate carboxykinase, manifested prior to the suppression of BAT thermogenesis, e.g. 6 hours after dapagliflozin treatment. Collectively, these results suggest that SGLT2i treatment acutely suppresses energy expenditure in BAT via regulation of an inter-organ neural network consisting of the common hepatic vagal branch and sympathetic nerves.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the rationale behind SGLT-2i causing a decrease in BP (systolic BP: 5mmHg, diastolic BP: 2mmHg on average)9 without a change in the heart rate remains unknown.10–12”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698 · cited 1×
“However, weight loss degrees after SGLT2i treatment appear to be much less than those predicted from the excreted glucose amounts in both human and animal studies [4,5].”
BackgroundSGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ferrannini, E., & Solini, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.243 · Cited by 458
Central control of thermogenesis in mammals
Morrison, S. F., Nakamura, K., & Madden, C. J. (2008) · Experimental Physiology · doi:10.1113/expphysiol.2007.041848 · Cited by 424 · cited 1×
“Activation of sympathetic nerves to BAT is responsible for UCP1 and PGC1α up-regulation, followed by enhancement of BAT thermogenesis [13].”
BackgroundSelf-citationEnergy Balance After Sodium–Glucose Cotransporter 2 Inhibition
Ferrannini, G., Hach, T., Crowe, S., Sanghvi, A., Hall, K. D., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-0355 · Cited by 359
Effect of Diet and Cold Exposure on Norepinephrine Turnover in Brown Adipose Tissue of the Rat
Young, J. B., Saville, E., Rothwell, N. J., Stock, M. J., & Landsberg, L. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110541 · Cited by 355 · cited 1×
“Therefore, we first examined norepinephrine (NE) turnover in BAT, as this result is known to reflect sympathetic activity to BAT [14].”
BackgroundThe Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Vallon, V. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051013-110046 · Cited by 348 · cited 4×
“Therefore, the development of therapeutic strategies for T2D that include decreasing body weight has long been awaited.”
BackgroundInfluentialImplications of nonshivering thermogenesis for energy balance regulation in humans
van Marken Lichtenbelt, W. D., & Schrauwen, P. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00652.2010 · Cited by 311
The Rostral Raphe Pallidus Nucleus Mediates Pyrogenic Transmission from the Preoptic Area
Nakamura, K., Matsumura, K., Kaneko, T., Kobayashi, S., Katoh, H., & Negishi, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-11-04600.2002 · Cited by 275 · cited 1×
“Therefore, we next examined the neural activity in the rRPa (Fig 2H), which contains the putative sympathetic premotor neurons responsible for thermogenesis in BAT [15].”
BackgroundSelf-citationNeuronal Pathway from the Liver Modulates Energy Expenditure and Systemic Insulin Sensitivity
Uno, K., Katagiri, H., Yamada, T., Ishigaki, Y., Ogihara, T., Imai, J., Hasegawa, Y., Gao, J., Kaneko, K., Iwasaki, H., et al. (2006) · Science · doi:10.1126/science.1126010 · Cited by 262 · cited 3×
“Furthermore, we previously showed that adenovirus-mediated expression of peroxisome proliferator-activated receptor γ2 in the liver induced acute hepatic steatosis, and increased BAT thermogenesis through afferent vagal signals originating in the liver [11].”
BackgroundMethodSelf-citationRenal glucose reabsorption inhibitors to treat diabetes
Bailey, C. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.011 · Cited by 217 · cited 1×
“Effects on increased urinary glucose excretion (UGE) by selective SGLT2 inhibition are not limited to blood glucose reduction in an insulin-independent manner but body weight reduction is also achieved [3].”
Background
Cited by
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y.-K., Yamamoto, T., Takano, H., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01127-z · Cited by 228
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Wilcox, C. S. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.11684 · Cited by 167
Tobita, H., Sato, S., Miyake, T., Ishihara, S., & Kinoshita, Y. (2017) · Current Therapeutic Research · doi:10.1016/j.curtheres.2017.07.002 · Cited by 140
“Dapagliflozin was also reported to reduce some of the complications associated with NASH in rodent models.(16,17) Therefore, in the present study, we evaluated the effects of dapagliflozin for the treatment of NASH in patients with T2DM.”
BackgroundThe Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
Wan, N., Rahman, A., Hitomi, H., & Nishiyama, A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00421 · Cited by 115
“(50) showed that acute administration of dapagliflozin significantly suppressed norepinephrine turnover in brown adipose tissue of mice, which reflects SNA in brown adipose tissue.”
BackgroundMolecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
Hou, Y., Zheng, C., Yen, T., & Lu, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217833 · Cited by 122
“[61] indicated that SNA originating from the brown adipose tissue could be decreased by SGLT2i.”
BackgroundPacker, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13229 · Cited by 100
Li, C., Luo, J., Jiang, M., & Wang, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838277 · Cited by 96
“Besides, SGLT-2i can also restrict weight loss by regulating inter-organ neural networks that inhibit brown adipose tissue-induced energy expenditure (Chiba et al., 2016).”
BackgroundNguyen, T., Wen, S., Gong, M., Yuan, X., Xu, D., Wang, C., Jin, J., & Zhou, L. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s258593 · Cited by 97
Erdogan, M. A., Yusuf, D., Christy, J., Solmaz, V., Erdogan, A., Taskiran, E., & Erbas, O. (2018) · BMC Neurology · doi:10.1186/s12883-018-1086-4 · Cited by 87
“Attenuating seizure activity via inhibition of SGLTs Once existing in obscurity, SGLTs are now a focus of interest in the medical community, after it was discovered that inhibition of SGLT2 can result in improved plasma glucose control for patients living with diabetes mellitus type 2 (DMT2).”
BackgroundInfluentialLee, J.-Y., Lee, M., Lee, J. Y., Bae, J., Shin, E., Lee, Y., Lee, B., Kang, E. S., & Soo, B. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0187 · Cited by 49
“However, the effects of SGLT2 inhibitors on energy expenditure and thermogenesis showed conflicting results [11,12].”
Wan, N., Fujisawa, Y., Kobara, H., Masaki, T., Nakano, D., Rahman, A., & Nishiyama, A. (2020) · Hypertension Research · doi:10.1038/s41440-020-0410-8 · Cited by 47
Couselo‐Seijas, M., Agra-Bermejo, R. M., Fernández, Á. L., Martínez‐Comendador, J. M., Sierra, J., Pérez, M. S., Rozados-Luís, A., González‐Juanatey, J. R., & Eirás, S. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.11.016 · Cited by 44
Quagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Paccone, A., Maurea, C., Scherillo, M., Merola, A., Giordano, V., Palma, G., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1289663 · Cited by 49
Kim, J. H., Ko, H. Y., Wang, H. J., Lee, H., Yun, M., & Kang, E. S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13905 · Cited by 34
“A previous study showed a significantly higher level of hepatic PEPCK in mice administered dapagliflozin compared to untreated mice.(27) However, in that study, changes in renal PEPCK”
ResultPharmacotherapy of Obesity: Limits and Perspectives
Rosa-Gonçalves, P., & Majerowicz, D. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00328-6 · Cited by 34
“A reduction in energy expenditure was also observed [119, 120].”
BackgroundWen, S., Nguyen, T., Gong, M., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s312527 · Cited by 30
Sawada, Y., Izumida, Y., Takeuchi, Y., Aita, Y., Wada, N., Li, E., Murayama, Y., Piao, X., Shikama, A., Masuda, Y., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.081 · Cited by 31
Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
Herat, L. Y., Matthews, J. R., Azzam, O., Schlaich, M. P., & Matthews, V. B. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01170-z · Cited by 33
Garg, V., Verma, S., Connelly, K. A., Yan, A. T.-K., Sikand, A., Garg, A., Dorian, P., Zuo, F., Leiter, L. A., Zinman, B., et al. (2020) · Metabolism Open · doi:10.1016/j.metop.2020.100039 · Cited by 31
Kumar, N., Kumar, B., Ashique, S., Yasmin, S., Venkatesan, K., Islam, A., Ghosh, S., Sahu, A., Bhui, U., & Ansari, M. Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112050 · Cited by 29
Takada, S., Sabe, H., & Kinugawa, S. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00100.2021 · Cited by 31
Kubota, Y., & Shimizu, W. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.03.009 · Cited by 37
“Administration of SGLT2 inhibitors can reduce the activity of the cardiac sympathetic nerve by reducing the activity of the cord and controlling the heart rate.(76) The precise mechanism for the increase of cardiac parasympathetic nerve activity with SGLT2 inhibitors demonstrated by our EMBODY trial is unclear, which…”
BackgroundBelli, M., Barone, L., Bellia, A., Sergi, D., Lecis, D., Prandi, F. R., Milite, M., Galluccio, C., Muscoli, S., Romeo, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314598 · Cited by 29
“SGLT2-Is reduce blood pressure also in the absence of an increased heart rate, suggesting that these agents may lead to a reduction in sympathetic nervous system (SNS) activity [100,101].”
BackgroundCintra, R. M. R., Moura, F. A., de Carvalho, L. S. F., Barreto, J., Tambascia, M. A., Pecoits‐Filho, R., & Sposito, A. C. (2019) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.65.1.70 · Cited by 32
Renoprotective Effects of SGLT2 Inhibitors
Vallon, V. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.005 · Cited by 33
Metabolic effects of antidiabetic drugs on adipocytes and adipokine expression
Yaribeygi, H., Simental‐Mendía, L. E., Barreto, G. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28420 · Cited by 29
“, 2013; Xu & Ota, 2010), or reduce it in brown fat (Chiba et al., 2016).”
BackgroundInfluentialLim, V. G., He, H., Lachlan, T., Ng, G. A., Kyrou, I., Randeva, H. S., & Osman, F. (2021) · EP Europace · doi:10.1093/europace/euab321 · Cited by 23
Iuchi, H., Sakamoto, M., Matsutani, D., Suzuki, H., Kayama, Y., Takeda, N., Minamisawa, S., & Utsunomiya, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-12106-y · Cited by 21
Bakkar, N. Z., AlZaim, I., & EL‐Yazbi, A. F. (2022) · Clinical Science · doi:10.1042/cs20220404 · Cited by 20
Mechanisms of current therapeutic strategies for heart failure: more questions than answers?
Khan, M. S., Shahid, I., Greene, S. J., Mentz, R. J., DeVore, A. D., & Butler, J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac187 · Cited by 22
Hosaka, S., Yamada, T., Takahashi, K., Dan, T., Kaneko, K., Kodama, S., Asai, Y., Munakata, Y., Endo, A., Sugawara, H., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00943 · Cited by 20
“Plasma leptin levels were determined with enzyme linked immunosorbent assay (ELISA) kits (Morinaga Institute of Biological Science, Yokohama, Japan) (Chiba et al., 2016).”
MethodSelf-citationDapagliflozin restores insulin and growth hormone secretion in obese mice
Huang, Z., Huang, L., Wang, C., Zhu, S., Qi, X., Chen, Y., Zhang, Y., Cowley, M. A., Veldhuis, J. D., & Chen, C. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0385 · Cited by 18
Dong, M., Chen, H., Wen, S., Yuan, Y., Yang, L., Li, Y., Yuan, X., Xu, D., & Zhou, L. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s399367 · Cited by 20
“Dapagliflozin significantly inhibited the turnover of norepinephrine (NE) in brown adipose tissue and the expression of c-Fos in the raphe pallidus lateral nucleus (RRPA) of the thermogenic sympathetic premotor neurons, to regulate an interorgan neural network composed of common hepatic vagal branches and sympathetic…”
BackgroundInter-organ insulin-leptin signal crosstalk from the liver enhances survival during food shortages
Takahashi, K., Yamada, T., Hosaka, S., Kaneko, K., Asai, Y., Munakata, Y., Seike, J., Horiuchi, T., Kodama, S., Izumi, T., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112415 · Cited by 19
Self-citationOjha, U., Reyes, L. M., Eyenga, F., Oumbe, D., Watkowska, J., & Saint-Jacques, H. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00486-6 · Cited by 17
Vrachatis, D. A., Papathanasiou, K. A., Iliodromitis, K. E., Giotaki, S. G., Kossyvakis, C., Raisakis, K., Kaoukis, A., Lambadiari, V., Avramides, D., Reimers, B., et al. (2021) · Drugs · doi:10.1007/s40265-021-01565-3 · Cited by 14
“Body temperature and systemic energy consumption are amendable to dapagliflozin CNS autonomic effects, as previously shown in animal models [28].”
BackgroundNew and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 14
“Early hemodynamic changes act via tubule–glomerular feedback to cause afferent arteriolar vasoconstriction, conferring renal-protective effects that may further improve cardiac function by reducing sympathetic activation 43–45 and oxidative stress 46–48 .”
SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
Lukic, N., Mačvanin, M., Gluvic, Z. M., Rizzo, M., Radak, D. J., Suri, J. S., & Isenović, E. R. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673251493231011192520 · Cited by 16
Hu, C., WANG, Y. C., Xi, Y., & YAO, X. M. (2020) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.spl.155 · Cited by 21
“Some studies have found that dapagliflozin can reduce the occurrence of complications of non-alcoholic steatohepatitis in rodent models[7,8].”
BackgroundHsu, C., Hsuan, C., Liao, D., Chang, J. K.-J., Chang, A. J.-W., Hee, S., Lee, H.-L., & Teng, S. I. F. (2023) · Life · doi:10.3390/life13041024 · Cited by 14
“Dapagliflozin has been shown to reduce norepinephrine turnover and decrease the expression of tyrosine hydroxylase, the rate-limiting enzyme of catecholamine biosynthesis, production in brown adipose tissue through decreased sympathetic input from the rostral raphe pallidus nucleus (rRPa) [158].”
BackgroundKusunoki, M., Hisano, F., Wakazono, N., Tsutsumi, K., Oshida, Y., & Miyata, T. (2021) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4626 · Cited by 10
“In addition, Chiba et al found that administration of the SGLT2 inhibitor dapagliflozin reduced energy consumption in mice, and reported that this was caused by reduced expression of uncoupling protein 1 (UCP1) in the brown adipocytes due to decreased sympathetic activity [15].”
BackgroundIto, S., Hosaka, T., Yano, W., Ito, T., Yasumura, M., Shimizu, Y., Kobayashi, H., Nakagawa, T., Inoue, K., Tanabe, S., et al. (2018) · Physiological Reports · doi:10.14814/phy2.13642 · Cited by 11
“Although gluconeogenesis was also previously demonstrated to be induced as compensation for the urinary glucose excretion promoted by SGLT2i (Chiba et al. 2016; Komiya et al. 2016; Obata et al. 2016), further investigation is necessary to address whether gluconeogenesis might be associated with…”
BackgroundDoes SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Dimova, R. B., & Tankova, T. I. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1298-4205 · Cited by 12
“Administration of dapagliflozin has been reported to exert a suppressive effect on the norepinephrine turnover in the brown adipose tissue of mice [86].”
BackgroundInter-Organ Communication Involved in Brown Adipose Tissue Thermogenesis
Takahashi, K., Yamada, T., & Katagiri, H. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4584-5_11 · Cited by 9
Self-citationRspo3-mediated metabolic liver zonation regulates systemic glucose metabolism and body mass in mice
Uno, K., Uchino, T., SUZUKI, T. A., 遥平, 佐., Edo, N., uno, K., Morita, K., Ishikawa, T., Koizumi, M., Honda, H., et al. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3002955 · Cited by 10
Self-citationBeneficial cardiovascular and remodeling effects of SGLT 2 inhibitors
Chrysant, S. G., & Chrysant, G. S. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2057949 · Cited by 8
Ferrari, F., Martins, V. M., Scheffel, R. S., da Silveira, A. D., Motta, M. T., Moriguchi, E. H., Santos, R. D., & Stein, R. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020985111 · Cited by 9
Kawarasaki, S., Sawazaki, H., Iijima, H., Ng, S.-P., Kwon, J., Mohri, S., Iwase, M., Jheng, H., Takahashi, H., Nomura, W., et al. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s269916 · Cited by 7
Piccirillo, F., Lanciotti, M., Nusca, A., Frau, L., Spanò, A., Liporace, P., Ussia, G. P., & Grigioni, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052103 · Cited by 6
Sato, D., Nakamura, T., Amarume, J., Yano, M., Nishina, A., Feng, Z., & Kusunoki, M. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.09.009 · Cited by 6
Yaginuma, H., Banno, R., Sun, R., Taki, K., Mizoguchi, A., Kobayashi, T., Sugiyama, M., Tsunekawa, T., Onoue, T., Takagi, H., et al. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.08.010 · Cited by 6
Nelson, A. J., Harrington, J., Kolkailah, A. A., Pagidipati, N. J., & McGuire, D. K. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.007 · Cited by 6
Verma, S. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz328 · Cited by 5
Lee, Y. K., Oh, T. J., Lee, J. I., Choi, B. Y., Cho, H. C., Jang, H. C., & Choi, S. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175946 · Cited by 4
Chiba, Y., Yamada, T., & Katagiri, H. (2018) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.17-00223-3 · Cited by 3
Self-citationSodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction
Profili, N. I., Castelli, R., Manetti, R., Sircana, M. C., Pagni, M., Sechi, G. L., Gidaro, A., Cossu, C., Bella, F., & Delitala, A. (2025) · Biomedicines · doi:10.3390/biomedicines13030720 · Cited by 4
“The third possible mechanism is the reduced activity of rostral raphe pallidus (rRPa) [23], which physiologically increases the cardiac sympathetic nerve activity and heart rate [24].”
Senousy, M. A., Abo-Elmaaty, R. M., Omar, N. N., & Abdelgawad, H. M. (2026) · Cell & Bioscience · doi:10.1186/s13578-026-01557-4 · Cited by 2
SGLT2 Inhibitors Improve Cardiac Failure by Reducing Whole-Body Oxygen Demand: A Hypothesis
Onoue, T., & Kataoka, M. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01220-z · Cited by 2
“Our findings were consistent with a recent study using animal models in which SGLT2 inhibitors reduced whole-body VO2, indicating a reduction in the demand for oxygen [33].”
ResultLee, H. G., Jung, I. H., Park, B. S., Yang, H. R., Kim, K. K., Tu, T. H., Yeh, J., Lee, S., Yang, S., Lee, B. J., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0261 · Cited by 2
“In accordance with clinical data, dapagliflozin-treated mice did not show critical body weight loss due to the compensatory metabolic processes to prevent the negative energy balance induced by increased urinary glucose output [17].”
BackgroundSee, A. Y. S., Blazeska, E., Shaban, A. A., Thomas, M. R., Nejad, S. H., Dornelles, A. S., Joyson, A., Burrows, S., Schlaich, M. P., & Thiruvengadam, S. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000541568 · Cited by 1
Chung, C., Lu, H., Chung, M., Wu, L., Huo, C., Kuo, L., Liu, C., & Chuu, C. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040260 · Cited by 2
Yazaki, M., Nabeta, T., Inomata, T., Maemura, K., Ooki, T., Fujita, T., Iida, Y., Ikeda, Y., Ishii, S., Naruke, T., et al. (2019) · Circulation Reports · doi:10.1253/circrep.cr-19-0080 · Cited by 1
Pires, L. D. S. (2017) · doi:10.47749/t/unicamp.2017.984589 · Cited by 1
2.自律神経系を介して脳が統御する 糖・エネルギー代謝調節機構の解明
Yamada, T. (2017) · 循環制御 · doi:10.11312/ccm.38.5
Self-citationShimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y., Yamamoto, T., Takano, H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13010690
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y., Yamamoto, T., Takano, H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13010693
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y., Yamamoto, T., Takano, H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13010696
Shimizu, W., Kubota, Y., Hoshika, Y., Mozawa, K., Tara, S., Tokita, Y., Yodogawa, K., Iwasaki, Y., Yamamoto, T., Takano, H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13010687
Visram, A. (2021) · TSpace (University of Toronto)
Metadata
- Authors
- Chiba, Y., Yamada, T., Tsukita, S., Takahashi, K., Munakata, Y., Shirai, Y., Kodama, S., Asai, Y., Sugisawa, T., Uno, K., Sawada, S., Imai, J., Nakamura, K., & Katagiri, H.
- Affiliations
- Tohoku University (JP)
- Nagoya University (JP)
- Corresponding author
- Yamada, Tetsuya
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-03-10
- Volume
- 11
- Issue
- 3
- Pages
- e0150756
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4786146
- OpenAlex
- W2295311043
- Cited by
- 71
- References
- 24
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 10 · 2021: 11 · 2020: 17 · 2019: 7 · 2018: 5 · 2017: 5
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by)
- Funders
- Japan Society for the Promotion of Science (15H05932, 26293215, 26461324, 25253067, 15K09407, 26670447, 26713009)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- dapagliflozin, SGLT2 inhibitors, energy expenditure, brown adipose tissue thermogenesis, sympathetic activity, norepinephrine turnover, c-fos, hepatic vagotomy, hepatic carbohydrate metabolism, UCP1, hyperphagia, weight loss
- MeSH terms
- Uncoupling Protein 1, Sodium-Glucose Transporter 2 Inhibitors, Animals, Benzhydryl Compounds, Adipose Tissue, Brown, Energy Metabolism, Gene Expression Regulation, Glucosides, Glycogen, Ion Channels, Liver, Male, Synaptic Transmission, Vagus Nerve, Proto-Oncogene Proteins c-fos, Thermogenesis, Mitochondrial Proteins, Carbohydrate Metabolism, Sodium-Glucose Transporter 2, Mice, Midbrain Raphe Nuclei
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.